Media Mentions

A multinational team of researchers has succeeded in turning human embryonic stem cells into three types of human heart cells.

Scientists are learning that even small genetic changes can make us more vulnerable to certain diseases or alter our responses to particular medicines.

Commentary on the status of personalized medicine in routine clinical care and the outlook for the future.

NIGMS is funding a large, interdisciplinary group of researchers, who are planning to test a wide array of approaches to promote wound healing.

Two teams of scientists, one supported by NIGMS, have sidestepped the use eggs or embryos and produced what appear to be human embryonic stem cells from skin cells.

Two teams of scientists, one supported by NIGMS, have turned ordinary human skin cells into what appear to be embryonic stem cells without using eggs or embryos.

NIGMS has awarded close to $1.5 million over 5 years to Binghamton University researchers to study how the malaria parasite evolved resistance to the once-effective medication, chloroquine.

The blood thinner warfarin has become the first widely used drug that will include genetic tasting data on its label, moving personalized medicine into the mainstream.

Researchers have found further evidence that normal genetic variations affect how the body responds to medications, but don't expect a DNA test before your next prescription.

NIGMS grantee Susan Lindquist is studying how misshaped proteins can lead to neurodegenerative disorders like Parkinson’s disease.

With funding from NIGMS, doctors at community hospitals as well as researchers at major research universities are working together to try to develop a prompt, rigorous, standardized treatment regimen to help patients diagnosed with sepsis.

The article features the emerging field of systems biology and the work of several NIGMS grantees who are at the center of it.

NIGMS grantee Roger D. Kornberg wins the Nobel Prize for revealing the molecular basis of eukaryotic transcription, the process of copying DNA into RNA.

NIGMS grantees Andrew Z. Fire and Craig C. Mello receive the Nobel Prize for their discovery of RNA interference.

NIGMS awards $13 million over four years to create four Centers for Innovative Wound Healing Research. The multidisciplinary centers will develop innovative therapies to understand and treat acute and chronic wounds.

NIGMS funds Princeton geneticist Bonnie Bassler, who studies quorum sensing, a chemical strategy bacteria use to join together into organized groups.

NIGMS grantee Mary V. Relling uses gene testing to customize medications for pediatric cancer patients.

NIGMS is funding a researcher who aims to predict which patients will respond well to a class of drugs called thiopurines, which are used to treat inflammatory bowel disease and cancer, among other ailments.

New pharmacogenetic tests may help find the right dose of the right medicine for individual patients.

A review of several studies that examine genetic variations and how they influence an individual’s response to particular medications.

Scientists with NIGMS funding in the form of a small business innovation grant have developed a method for producing genetically modified chickens. The advance could lead to new human therapeutics.

A new study supported by NIGMS indicates that successful cancer treatment depends more on a tumor’s reaction to medications than its origin.

The Washington Post featured colorful images generated by NIGMS scientists and previously highlighted in the NIGMS monthly electronic newsletter Biomedical Beat.

Researchers supported by the PSI and the NIGMS Small Business Innovation Research Program have developed a miniature synchrotron that could transform many fields of biomedical research.

Results from the latest NIGMS-supported pandemic flu modeling project, which simulates outbreaks in the United States.